PRVB Provention Bio Inc.

12.81
+0.81  (+7%)
Previous Close 12
Open 12.08
Price To Book 9.78
Market Cap 478,601,609
Shares 37,361,562
Volume 595,465
Short Ratio
Av. Daily Volume 1,067,847

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b top-line data May 8, 2019 noted primary safety and tolerability endpoint met but efficacy and other secondary endpoints were not met.
PRV-300
Ulcerative Colitis
Phase 3 trial initiation announced April 9, 2019. Enrollment to be completed in 2020.
PRV-031 (teplizumab)
Type 1 diabetes
Phase 2a data due 4Q 2019.
PRV-6527
Crohn's disease
Phase 2b trial to commence 2020.
PRV-015
Celiac disease
Phase 1b to commence 2H 2019.
PRV-3279
Systemic Lupus Erythematosus (SLE) and Lupus nephritis (LN)

Latest News

  1. 5 Best Biotech Stocks of 2019 So Far
  2. ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
  3. Provention Bio Announces Termination of Public Offering of Common Stock
  4. A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years
  5. Could The Provention Bio, Inc. (NASDAQ:PRVB) Ownership Structure Tell Us Something Useful?
  6. The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut
  7. Provention Bio Reports First Quarter 2019 Financial Results
  8. Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
  9. Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease
  10. Provention Bio, Inc. (PRVB) Shares March Higher, Can It Continue?
  11. Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
  12. Provention Bio Announces Key Additions to its Senior Management Team
  13. Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors
  14. Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  15. Provention Bio to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 19, 2019
  16. Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference
  17. Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)
  18. Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B
  19. Are Insiders Buying Provention Bio, Inc. (NASDAQ:PRVB) Stock?
  20. Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium